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Experimental technique may have future
applications for lung and other cancers.

Antisense RNA technology successfully
blocks K-ras-induced cancer
Lab to Clinic

Jack A. Roth is chairman of
the Department of
Thoracic Surgery

Can anything stop the rapid and destructive proliferation of cancer cells while preserving normal
tissue? The answer may be yes, according to recent
findings by a team of researchers at The University of
Texas M. D. Anderson Cancer Center. The team is
headed by Jack A Roth, M.D., chairman of the
Department of Thoracic Surgery. They used a relatively new technology in which "antisense RNA"
inactivates the K-ras oncogene, a gene known to play
a role in the development oflung cancer. Roth and
his team's studies are still limited to the laboratory,
but ~ing antisense RNA to inactivate oncogenes
may eventually have clinical applications for lung and
other cancers.
The team's work is based on oncogene theory, one
of the most widely accepted explanations for the
origin of tumors. The existence of oncogenes, genes
that promote the development of cancer ~hen they
are activated by carcinogens, had been suspected by
tumor biologists since early in this century; these
suspicions were confirmed in 1975 when an oncogene
was first characterized in normal human cells. Since
then, about 60 different oncogenes have been identified. However, said Roth, "the name oncogene is
really a misnomer. Oncogenes are not present in cells
to cause cancer. They are normal genes present in all
normal cells, and they perform very vital functions
related to cell growth and cell division. They have in
some way become activated by mutation, translocation, or deletion to perform functions that they don't
normally perform."
Some oncogenes work in a dominant fashion; that
is, change in only a single allele of the gene is sufficient to cause that cell to become cancerous. In other
cases, these oncogenes have a negative function: in
their normal state, they suppress the growth of the
cell, and only when both alleles of the gene are lost
is the cell likely to become cancerous. These "negative" genes actually protect against getting cancer;

they are usually called tumor suppressor genes. (The
classic example is the retinoblastoma gene: both
copies of the gene must be deleted or inactivated in
order for the retinoblastoma to develop.)
Roth's team selected the ras family of oncogenes
for their studies ofcell growth in 1ung cancer. The ras
family includes the Kirsten rat sarcoma virus (K-ras)
oncogene, the Harvey ras (H- ras) oncogene, and
the N-rasoncogene. Originally identified in the rat
sarcoma virus, K-raswas one of the first oncogenes
to be implicated in human cancer. K-ras is one of the
dominant, or what Roth calls positive, oncogenes. It
produces a protein called p21 (because its molecular
weight is 21,000) that binds to the inner surface of
the cell membrane and acts, probably, as a transducer, modifying signals that reach the cell's surface
in some way so that the cell can interpret the signal.
Mutations in the oncogene alter the protein's transducing ability. The precise mechanism of signaling
and function, however, is not clearly known.

Normal function ofK-rasis altered
The researchers did know, however, that single
nucleotide mutations in the ras genes in human cells
caused these cells to take on the features of cancer
cells: rapid growth, tissue invasion, and metastasis. In
the mutated state, ras genes are constantly activated
rather than being switched on and off by the signals
at the cell surface. Ras investigators think this constant activation has something to do with the cell
becoming malignant. Therefore, the M. D. Anderson Cancer Center team wanted to figure out a way
to inactivate ras. Previous studies had found ways to
do this, but these methods had also destroyed the
cells needed for normal functioning. A new method
was needed that would inactivate raswhile preserving normal cells, targeting only the mutated genes so
that the normal rasgene could help keep the cell alive
and functioning.
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'-We' re trying to alter the cancer
cell directly by altering the
expression of cancer genes~
•

•

Figure 1

"Anti.sense" technology counteracts the cancercausing protein
The advent of antisense RNA technology made
such an objective possible. In Roth's studies, an
antisense RNA construct was injected into a commonly used experimental lung cancer cell line in
which K-ras was known to spontaneously mutate.
The construct caused the cells to express an artificial
gene that produced messenger RNA that was exactly
complementary ("antisense") to the abnormal RNA
produced by the cancer cell. For example, for all
cytosine nucleotides in the cancer cell's RNA, the
antisense RNA contained complementary guanine
nucleotides that bound to the cytosines. The same is
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true for the other pair of complementary nucleotides: uracil and adenine. The binding ofthese complementary nucleotides forms a K- ras-antisense RNA
duplex that essentially inactivates the abnormal RNA's
ability to produce the cancer-causing protein (Figure
1). In these experiments , the growth rate of the cells
slowed to about one third of their malignant rate,
closer to the normal rate of growth, and continued
to function normally. When the antisense RNA was
injected into cells that did not have mutated K-ras,
the cells were unaffected. The team also tested these
cells in animals. The cells with the cancer-causing
mutated gene were injected into nude mice, which
began to develop fatal tumors. The mice whose
injected cells were first treated with antisense RNA
did not develop these tumors. This inactivation of
the K- rasprotein had no effect on the other rasgene
products.
Future research will focus on the clinical applications of this technique. Although others have heralded the development as a step toward gene therapy,
Roth sees the technique as more promising in the
area of what he calls molecular therapy. "We're
trying to alter the cancer cell directly," he said, "by
altering the expression of cancer genes." He doubts
whether gene therapy, which has gotten much attention in recent years, will have many applications in
cancer. He sees gene therapy, which he defines as
inserting a normal gene into a cell to produce a
protein that cannot be produced by the defective
host gene, chiefly as a drug delivery system. Molecular therapy, on the other hand, involves changing
how the gene behaves. Roth sees the major challenge
in this technique as increasing the efficiency ofuptake of
th-e--antisense-eonstmets-by the cancer cells, expe ·
men ts now under way are looking at viral systems for
delivering the antisense RNA. For example, a
retrovirus carrying the antisense RNA would infect
the proliferating cancer cells and leave the normal
cells unaffected. Although Roth warns that such a
method is far from perfected, he is optimistic that
such an agent may be ready for clinical trials in a few
years.
Roth also points out that cancer cells probably
have about 15 to 20 different gene abnormalities;
researchers are beginning to identify many ofthese in
continued on page 7
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Renowned as a giant of pediatric oncology and beloved by patients, colleagues, and friends, Grant Taylor,
M.D., is recognized internationally as a founding father
of pediatric oncology in the nuclear age. After receiving
his M.D. from Duke University School of Medicine, he
entered the military and was decorated for valor as a
battlefield doctor in World War II. In the late 1940s, he
helped establish the Atomic Bomb Casualty Commission
(ABCC) and directed its initial study of the effects of
radiation bomb survivors in postwar Japan where he
recorded some of the first cases of lymphoid neoplasia
resulting from radiation exposure. Taylor is remembered

not only for his medical skill and leadership, but also for
his compassion and deep sensitivity to the trauma of the
bomb survivors. His tenure at the ABCC set the stage for
his years at The University of Texas M. D. Anderson
Cancer Center, which he joined in 1954 as head of
pediatric oncology. At M. D. Anderson Cancer Center,
he assembled one of the most effective teams to manage and develop therapies for childhood leukemia.
-James M. Bowen, Ph.D., Professor
of Virology, Vice President
for Academic Affairs

Hiroshima, 1949Science in the midst of suffering.

The human face of data
On a small hill at the edge of Hiroshima in 1949, first visit to Japan, his experience there would be
the Atomic Bomb Casualty Commission (ABCC) colored by powerful images of destruction and inestablished its permanent quarters in eight buildings tense human pain. None of his research could be
of corrugated iron. Grant Taylor, M.D., then direc- performed without in some way reminding him of
tor of the ABCC, hoped the location would attract some aspect of the horror of the bomb.
bright American researchers to study the effects of
Awed by the devastation
the atomic bomb on Hiroshima's survi"I made my first visit to Japan in 1946
vors. The buildings were spare, but the
during my military assignment in Seoul,"
view was beautiful. Amidst tall pine, one
Taylor said. "I went first to Hiroshima,
could see the seven small pennisulas of
on to Nagasaki and Sasebo, and then
Hiroshima below, where the delta ofthe
back to Hiroshima. I'll never forget the
Ota river met the Inland Sea, and on the
devastation. But the physical destruchill, far from the hypocenter ofthe blast,
the atmosphere was serene.
tion was only the tip of the iceberg in
terms of the total human impact. The
And perhaps deadly. Taylor,nowprofessor emeritus at The University of
extent of outright deaths, those that
Texas M. D. Anderson Cancer Center
slowly died, and the crippling and the
Grant Taylor,
professor emeritus
and The University of Texas Health
physical and mental anguish of untold
Science Centerarrlouston, reca:l:lsd:Tir
thousands was yet: n:riJe evalua~'
While in Nagasaki, Taylor explored the remains of
in 1949 little was known about radiation. How long
would the bomb's effects last, and would situating the pathology building in the medical center. "Two
the ABCC in Hiroshima endanger the researchers? walls of the main pathology unit remained standing.
As a precautionary measure, workers were housed in Against one of them, on a shelf, a stack of histologic
Kure, a small town outside Hiroshima, and were slides had melted into a solid block ofglass; some had
melted so that the glass hung in long 'icicles' from the
bussed into the ABCC each day.
The ABCC's purview was strictly research. It was edge of the shelf. I could reconstruct the furnishings
to retrieve as much medical data as possible about of the room by the way the ashes had fallen."
Taylor made his way to the medical school, one of
survivors, focusing on their location at the time ofthe
the few structures that remained standing. He found
blast and the symptoms they experienced since then.
But it became obvious to Taylor that his endeavors the dean sitting behind what Taylor calls an "improcould not remain dispassionately scientific. From his vised desk."
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'-He was the only one who survived.
He was completely submerged when
the bomb exploded"
•
Taylor could find no words that seemed appropriate. "We just sat and looked at each other. Finally, he
told me that he had remained in his office late the
night before the bomb to reprimand one of his
professors and then departed for his home in the
country. Now he was obsessed with the thought that
there was no way to unsay the words he had used."
The dean then offered to introduce Taylor to a
medical student. "The student had gone swimming
with friends from the pathology laboratory," Taylor
said. "He had been reluctant to return and pled with
his colleagues to wait for him while he took one more
dive. He was the only one who survived. He was
completely submerged when the bomb exploded."
After his military assignment, Taylor accepted a
position at Duke University Medical School in
Durham, North Carolina. "My research program
progressed very nicely, and as associate dean I enjoyed my student and faculty responsibilities," Taylor said. But that was to change when he accompanied Wilbert C. Davison, M.D., dean of the school,
to Washington, D.C., for a planning meeting of the
ABCC.
Data analysis a daunting task
He had heard about the newly formed commission, but had some doubts about its feasibility. What
kind of data should they gather? No one was quite
sure. "Aside from some mouse studies by Ernest
Goodpasture, little in the scientific literature was
helpful to those interested in studying the medical
effects of irradiation," Taylor said.
But even if appropriate data were gathered, the
amount would be massive. How could such data be
analyzed? While Taylor was in Washington, D. C., his
doubts were allayed by two encounters, one with an
emphatic man, the other with an odd-looking contraption.
"Dr. John Lawrence ofthe UCLA Medical School
had a big impact on me. He told me, 'When you don't
know what to look for, comprehensively examine your
patients and compare them with appropriate controls!"'
Simple advice, but said with enough conviction to
give Taylor confidence.
Later Taylor visited the Library ofCongress, where
he saw a strange mechanical device. "It was primarily
a cataloging system for book titles and author names.
Information was stored on 16-mm film. The film
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would stretch every time the braking system was
applied, but I was very impressed, for here was a
device that could be used to store large amounts of
medical data. The availability of a machine like the
one I saw ( Taylor later arranged for one to be sent to
Hiroshima) and Dr. Lawrence's comments were the
reason for my going to the ABCC."
Courtesy a veil for sorrow
So it was that Taylor returned to Hiroshima in
1949. Surprisingly, he found the Japanese courteous
and friendly. "Although food was scarce and they
lived in dwellings largely made with debris from the
blast, they generally did not react toward us as
though we had been the cause of their tragic misfortune," he said.
But beneath the courtesy there was much sorrow.
Taylor was invited by the chairman ofthe city council
to attend a party, which would also be attended by
the governor, the mayor, and other local officials.
Taylor and other ABCC personnel typically refused
such invitations as graciously as they could. The
prospect ofbeing entertained while people in the city
were under such economic hardship was something
Taylor wanted to avoid. But he accepted this invitation because ofthe arrival ofDr. Alan Gregg from the
Rockefeller Foundation. "The Japanese were very
excited about his arrival, so we accepted their invitation."
The party began with a cordial introductory welcome by the chairman of the city council. "He stood
in the center of the room, facing me," Taylor said.
"And then his manner abruptly changed. In a deeply
emotional voice he said, 'Tonight I am going to tell
it!' He told ofthe blast, first the blinding bright flash,
the thundering crash, the demolition of his home,
the darkness and the heat. Frantically he had moved
through the wreckage ofhis home, which was beginning to burn to the area where his children slept. His
home was a tangled mess of planks, tile, wooden
frames, and sheets of zinc roofing. He could not
reach where his children had been sleeping, so he
tried to crawl under the wreckage. He was choking
with smoke; it was warm and he couldn't see. His
outstretched hand touched a foot. It was one of his
sons; nearby he located the body of his other son.
Both were dead.
"The chairman, who had been standing in front of
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me, slowly turned and made his way across the room
to his ozan, where he stood, sobbing, and his shoul·ders shaking. His sobs were the only sound in the
room. I did not know what to do, but with an
outstretched hand I rose and made my way slowly
toward him. H e shoved his hand into one of his
pockets and brought out an engraved Zippo lighter
I had previously given him. He raised his hand and
shouted 'Okay! Okay! Okay!' The party was over."
It was such events, the courtesy of the Japanese
notwithstanding, that colored the experience of
every American in Hiroshima. Every survivor of the
blast probably had a similar tale to tell, which made
conducting scientific studies all the more difficult.
Using Japanese midwives as translators, ABCC personnel would go to the homes of survivors, many of
whom were very ill, to interview them. In some cases,
however, survivors were picked up and brought to
the ABCC complex, which did not go over very well
with some of the Japanese. "Some were very suspicious of us taking sick people, some of them on
stretchers, to the facility," Taylor said.
Three ABCC researchers go to M. D. Anderson
Ironically, the data that Taylor spent years gathering had no direct application to his subsequent career
as a pediatric oncologist, but the ABCC had a
tremendous impact on M. D. Anderson. Taylor had
heard about a fledgling cancer hospital in Houston
named The University of Texas M. D. Anderson
Hospital and Tumor Institute. As his term with the
ABCC came to an end, he spoke with the hospital's
director, R. Lee Clark, M .D., at a meeting in Washington. Clark convinced Taylor to direct pediatric
cancer research at M . D. Anderson.
But Taylor did not go to M . D. Anderson alone.
During his tenure at the ABCC, he met two bright,
young physicians. One a Houston woman educated
in biology and chemistry at Rice University and in
medicine at Duke University, and the other a Japanese-American physician whose medical training had
been temporarily interrupted by detainment in a
WWII internment camp.
Margaret P. Sullivan, M.D., spent 18 months at
the ABCC beginning in 1952. She and her group
were responsible for performing health examinations
of 5,000 children-2,500 who had been exposed to
the bomb's radiation and 2,500 who had not. Impressed by her keen intelligence and toughness,
Taylor later asked her to join his staff at M. D.
Anderson. Sullivan works there to this day. "It was
tough in those days for women in medicine. She
handled herself so well, I wanted her on my staff,"
Taylor said.
Taylor was also accompanied by Wataru W. Sutow,

M.D., who at the ABCC had been in charge of the
pediatric research group. Sutow had spent one twoyear term at the ABCC beginning in 1947, but in
1950 he was called into the U.S. Army Medical
Corps. After officer training, he returned to the
ABCC for an additional term. His ability to develop
an instant rapport with the children amazed Taylor.
Sutow was renowned for the "Sutow magic toy" (a
tape measure, much loved by infants) and for his
ability to captivate preschoolers by drawing a butterfly or a flower on the back of their hands. Sutow
remained a physician atM. D. Anderson until 1981,
when he died of lung cancer. Ever the scientist,
Sutow demanded that his colleagues assure him that
tissue methotrexate levels would be taken and studied after his death.

-

Taylor said that one thing that he, as well as Su tow
and Sullivan, brought back with them was hope. "We
had begun to see an increased incidence ofleukemia
at the ABCC, a late effect ofthe radiation. By the time
we came to the States, chemotherapy was beginning
to show promise for leukemia. After we had seen the
death in Hiroshima, the possibility of life was very
exciting."

M. D. Anderson pediatric
staff, 1955. Left to right:
Drs. Noriaki Ida, Margaret
P. Sullivan, Wataru W.
Sutow, Sadahisa
Kawamoto, Arthur
Kirschbaum, Grant Taylor.

Portions of this article were adapted, with permission,
from Remembrances and Reflections, written by Grant
Taylor and edited by DonMaconandJohn G. McGovern,
M.D., The University of Texas Health Science Center at
Houston, Houston, 1991 .
Physicians who desire additional information may write
Grant Taylor, M.D., Department of Continuing Education, The University of Texas Health Science Center at
Houston, P.O. Box 20367, Houston, Texas 77030, or
call (713) 792-4671.
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"When the breast mound is restored
before the patient recovers from her
anesthetic, much of the psychological
pain ... is avoided"
Figure 1A. A 31-year-old

woman with T2
breast cancer shown
preoperatively.

Breast reconstruction
continued from page 8
of the shorter incisions and limited exposure, but
when properly executed allows the reconstructive
surgeon to closely match the shape of the original
breast (Figure 1). Moreover, if the scars are limited
to the areolar area and to the upper lateral quadrant
ofthe breast, low-cut dresses and bathing suits can be
worn without fear of scars becoming exposed. If
reconstruction is being accomplished with simple
implant insertion or with tissue expansion, the additional preserved skin allows much better ptosis and a
better chance of achieving a normal breast shape
(Figure 2 ). Even when flaps are used to replace
missing skin, however, the amount of exposed distant skin (which may have a different color or texture
from that ofthe surrounding normal breast skin) and
the extent of visible scarring are reduced. For these

reasons, the cosmetic appearance of immediate breast
reconstructions is almost always better than that of
reconstructions performed at some later time.
Figure 1 B. Same woman

two years after right
modified radical mastectomy with immediate
TRAM flap breast
reconstruction.
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Risk of tumor recurrence not increased
Many patients and physicians have asked if immediate reconstruction and preservation of uninvolved
breast skin adversely affects the risk of tumor recurrence. Provided that patients are properly selected,
we have found that such risks are not increased. Out
of 140 patients with early breast cancer followed for
over one year, only three have developed local recurrences. This number is actually lower than that
expected from a comparable group after a more
conventional mastectomy, supporting the concept
that preservation of uninvolved skin is not harmful.
Appropriate candidates for a skin preservation
mastectomy include patients who have T2 and smaller
tumors (less than 5 cm in diameter) without clinical
skin involvement. Any skin within 1 cm ofthe tumor
should be removed, along with the nipple, the areola,
and any biopsy scars. Patients with advanced tumors,
who will require postoperative radiotherapy, are not
appropriate candidates. Although they still may be
candidates for eventual breast reconstruction, it is
usually better to do so later.
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-'The cosmetic appearance of
immediate breast reconstructions
is almost always better~
•

•

•

•

•

Antisense RNA technology
continued from page 2

Figure 2. A 52-year-old woman shown one year after left

modified radical mastectomy with immediate reconstruction using tissue expansion followed by insertion of a
silicone prosthesis.

a variety of cells. It appears that these gene abnormalities may be very dependent on one another and
function in a cascade; that is, a certain sequence of
mutations or abnormalities must occur to cause a cell
to become malignant. In the K-rasexperiments, the
team was very surprised that interrupting just one
event caused such a profound change in the character
of the cells. They did not expect it to cause such a
large decrease in tumor growth or growth rate. A
follow-up experiment on another gene abnormality,
p53, which is found in many different kinds of
tumors, also showed a profound and dramatic decrease in malignant cell growth. The team concluded
from this finding that it may not be necessary to
reverse every one of the 15 or 20 malignant changes
that are present in the cancer cells; it may be enough
to interrupt only one or two of them.

Purpose is functional as well as cosmetic
The convenience and other advantages of immediate reconstruction appeal to mastectomy patients
and have probably induced some women to undergo
reconstruction who perhaps would not have done so
had the reconstruction been delayed. Is this a disadvantage? I think not. Most such women state that
they are very glad that they had reconstruction and
find that their lives are made more normal and Molecular therapy may have uses for cancer
satisfying because ofit. The purpose of breast recon- prevention
struction is not solely cosmetic. Its goal is rather to
Roth foresees that this technique may be broadly
restore the ability to wear normal clothing and applicable to a wide variety of tumors. The prevenparticipate in normal, everyday activities without tion of cancer may be another application; alteration
being limited by surgical deformity. We at M. D. of the genetic changes may be possible at the
Anderson Cancer Center believe that women who premalignant stage. Roth's team has, in fact, recently
are restored to good health without physical defor- identified oncogene mutations in premalignant lemity are better able to return to an active role in sions. This gives researchers the opportunity to
society, which contributes not only to their own identify patients who may be at risk of developing
happiness but to that of others as well. Society as a cancer very early and to try to manipulate the genes
whole benefits when cancer patients are al5le o ~ tyefore-rh~Terd~lnps-:-Furexample-;-p~atrents
return to their roles as workers, caregivers, and who smoke, have changes in their bronchial mucosa,
taxpayers. Although reconstruction admittedly does or have had previous lung or throat cancers have a
increase the early cost ofmedical care, it returns both high risk of developing lung or esophageal cancer.
economic and intangible long-term benefits when it These patients would be monitored very carefully for
encourages patients to abandon the role of "disabled premalignant conditions, and molecular therapy could
invalid" and instead to become productive and be used to inactivate the genes causing these condicontented members of society once again.
tions before they become malignant.
Physicians who desire additional information may write
Stephen S. Kroll, M.D., Reconstructive Plastic Surgery
Service, Box 62, The University ofTexas M. D. Anderson
Cancer Center, 1515 Holcombe Boulevard, Houston,
Texas 77030, or call (713) 794-1247.
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Two procedures but one operation: Plastic
surgeon works with oncologic surgeon to
reconstruct the breast.

Immediate breast reconstn,ction reduces
the trauma of mastectomy
Treatment Update

Stephen S. Kroll is an
associate professor of
plastic surgery in the
Reconstructive Plastic
Surgery Service, Division
of Surgery

By Stephen S. Kroll, M.D.
Since late in the past decade, The University of
An erson Cancer Center has been a
pioneer in the concept of breast reconstruction
immediately following mastectomy. This early performance ofreconstruction has become very popular
among women who must undergo mastectomy. The
first and most obvious reason for this is convenience
for the patient. She can obtain her breast mound
reconstruction without having to take time off for a
separate hospital admission, and she leaves the hospital with her breast contour restored. This early
rehabilitation not only preserves time and effort, but
also provides a second advantage in that she is spared
the psychological trauma of having to live with
physical deformity. Although not all women are
bothered by such deformity, often those who are

young or single are considerabl up t b it. When
the breast mound is restored e en b for th pati nt
recovers from her anesthetic muc
olo ·
·
loss of the br
d.
A third advantage is that of reduced expen s. The
patient, already obligated to remain in the ho pital
for at least a few days recovering from her mastectomy,
can recover from her reconstruction at the same time for
little or no additional cost. Anesthetic risks and costs
are also reduced, since she is alread anesthetized
when the reconstruction begins and a separate anesthetic induction is not required.
Another significant benefit is the aestheticall improved outcome. When reconstruction is immediate, the reconstructive surgeon and the oncologic
surgeon can work together to conceal the scars and
preserve uninvolved breast skin. This team\J ork adds
to the technical difficulty of the mastectom because
continued on page 6

